TB-4 vs TB-500: what's the actual difference?

Last updated 2026-07-24

What is the difference between TB-4 and TB-500?

Thymosin beta-4 (often written Tβ4 or TB-4) is a naturally occurring 43-amino-acid protein found in almost every cell in the body. It's one of the most abundant members of the beta-thymosin family and it binds actin, which is why researchers have studied it for cell migration and wound healing for decades. TB-500 is not the same molecule. It's a name used in the gray-market peptide trade for a synthetic product described as covering the actin-binding region of Tβ4, roughly residues 17-23, sometimes sold as an acetylated fragment. A 2012 analytical chemistry paper actually synthesized and characterized this exact fragment, the N-terminal acetylated 17-23 piece of thymosin beta-4, specifically because it was 'suspected to possess doping potential' ^[1]. That phrasing alone tells you a lot: this is a compound built for the doping-control literature to have something to test for, not a compound that came out of a drug development pipeline with FDA oversight. So the short version: TB-4 is the whole native protein. TB-500 is a shorter, lab-made stand-in for part of it, sold outside any approved drug framework. Related family, different molecule, different evidence base. See our TB-500 mechanism of action page for more on how the fragment is thought to work at the cell level.

Is TB-500 the same as thymosin beta-4?

No, and conflating the two is one of the most common mistakes in peptide forum discussions and product listings. TB-500 is marketed as derived from Tβ4's active site, but it isn't the full 43-amino-acid sequence, and products sold under that name aren't standardized the way an approved drug would be. A 2024 mass spectrometry paper set out specifically to quantify 'TB-500 and its metabolites' as distinct analytes from native thymosin beta-4, using UHPLC-Q-Exactive Orbitrap MS/MS in both in-vitro systems and rats, and screened the breakdown products for wound-healing activity ^[2]. The fact that a peer-reviewed lab needed a dedicated method to tell TB-500 and its metabolites apart from native Tβ4 in blood and tissue is itself evidence that these are chemically distinguishable entities, not synonyms. If you see a supplier or a forum post using 'TB-500' and 'thymosin beta-4' interchangeably as if they're the same vial of the same molecule, that's a sign the source isn't being careful with the chemistry.

TB-4 vs TB-500: side-by-side comparison

The compounding-law columns matter more than they look. Neither TB-4 nor TB-500 appears on the FDA's 503A bulk drug substances list ^[3] or the 503B bulk drug substances list ^[4], the two lists that determine what a compounding pharmacy can legally use to prepare a human drug product. That's a regulatory fact, not a marketing claim, and it's worth checking yourself on the FDA's own bulk substances pages ^{[7] [8]}.

What does the actual research say about TB-500?

Most of what exists is preclinical, analytical, or doping-detection literature, not controlled human trials for injury recovery. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides in orthopaedics broadly, covering applications, challenges, and future directions for the field ^[9]. A companion 2026 paper in The American Journal of Sports Medicine framed injectable peptide therapy as a primer for orthopaedic and sports medicine physicians, again at the level of the broader peptide category ^[10]. A third 2026 paper in Sports Medicine (Auckland) specifically reviewed the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance ^[11]. That paper's framing, drawing a line between 'approved' and 'unapproved' peptide products, is exactly the distinction a reader should keep in mind: TB-500 sits on the unapproved side of that line. On the mechanistic end, the 2024 UHPLC-Orbitrap paper screened TB-500's breakdown products for wound-healing activity in vitro, which is cell-culture evidence, not evidence from injured humans ^[2]. None of these papers report a completed human randomized trial establishing a dose or a recovery timeline for TB-500 in tendon or muscle injury. If a seller shows you a study, ask whether it was done in cells, in rodents, or in people. That answer changes the whole conversation.

Why does most TB-500 research come from anti-doping labs, not medicine?

Because that's largely who's had a reason to study it closely. Look at the citation list for TB-500 and you'll notice a heavy tilt toward doping-control chemistry rather than clinical medicine, and that pattern is itself informative. A 2012 paper in the Journal of Chromatography A developed a liquid chromatography-mass spectrometry method to detect TB-500 in equine urine and plasma ^[5], because it was already showing up as a suspected performance product in horse racing. A 2013 paper extended similar LC-MS work to seven bioactive peptides including TB-500 in horse plasma ^[6]. A 2017 paper in Analytical Biochemistry studied adsorption effects for several doping-relevant peptides, TB-500 among them, alongside insulin lispro, Synacthen, and GHRP-5, essentially solving the practical lab problem of the peptide sticking to plastic tubing and giving false negatives ^[12]. Other papers built out the broader detection toolkit: a 2014 review on analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls ^[13], a 2014 Expert Review of Proteomics paper on detecting peptidic drugs and analogs in sports doping generally ^[14], a 2015 Journal of Peptide Science paper on in-vitro metabolism models for small peptide hormones in drug testing ^[15], a 2016 Journal of Separation Science paper on screening sub-2kDa peptides by direct urine injection and ion mobility MS ^[16], a 2016 Journal of Proteomics paper comparing in-vitro metabolism model systems (enzymes, serum, liver and kidney microsomes, liver S9 fraction) for synthetic doping peptides ^[17], and a 2016 Drug Testing and Analysis paper on solid-phase extraction methods for small bioactive peptides from human urine ^[18]. That's a stack of methods papers built to catch the compound, not to treat a patient with it.

Is TB-500 banned in sports? What is its WADA status?

Yes, TB-500 falls under WADA's prohibition on peptides and growth factors, which is exactly why the anti-doping chemistry literature above exists in the first place. The 2012 equine detection paper and the 2013 horse-plasma paper were both explicitly framed as doping-control work ^{[5] [6]}, and racing labs don't build LC-MS assays for compounds nobody's worried about. For competitive athletes tested under WADA or an affiliated body's code, using TB-500 (or thymosin beta-4 delivered as an unapproved synthetic product) carries the same risk as any other prohibited peptide: a positive test, a sanction, and a public record. This isn't a gray area worth arguing about. If you compete under a testing authority, treat this compound as off-limits, full stop.

Can you buy TB-4 or TB-500 as a standalone product?

Not through a legitimate pharmacy channel, no. There's no standalone TB-500 SKU moving through licensed compounding pharmacies. Where TB-500 shows up in a provider-reviewed dispensing pathway, it's formulated as part of a combined BPC-157/TB-500 blend, not sold alone. That's partly a regulatory reality: neither peptide is on the FDA's 503A bulks list ^[3] or 503B bulks list ^[4], the two lists that govern what compounding pharmacies operating under 21 U.S.C. § 353a ^[19] can legally use for human prescriptions. The FDA's own bulk drug substances page for 503A compounding ^[7] and its current nominated-substances list ^[8] are the primary places to check status yourself before trusting any seller's claim about legality. Raw peptide sold online outside a pharmacy relationship, labeled 'research use only,' is a different category entirely: unregulated as a drug product, unverified for purity, and not something a compounding pharmacy stands behind. If a provider does prescribe a BPC-157/TB-500 blend after reviewing your history, that's the route with actual clinical oversight attached. TB-500 Co works from that provider-reviewed, pharmacy-dispensed model rather than pointing people to raw peptide vendors.

What about thymosin beta-4 in aging and general tissue repair research?

Native Tβ4 shows up in the aging and regenerative medicine literature more than TB-500 does, largely because it's the actual endogenous protein researchers can study without the fragment-identity confusion. A 2026 paper in Frontiers in Aging reviewed therapeutic peptides in gerontology, covering mechanisms and applications relevant to healthy aging broadly ^[20], with thymosin-family peptides part of that wider peptide landscape. This is worth flagging because gerontology framing sometimes gets stretched into anti-aging marketing claims that outrun the evidence. The paper is a mechanisms-and-applications review, not a clinical trial proving TB-500 or Tβ4 slows aging in humans. Treat any anti-aging pitch built on this citation with real skepticism until human outcome data exists.

How does dosing differ between TB-4 research and TB-500 products sold online?

There isn't a validated human dose for either one, which is the honest and slightly unsatisfying answer. Preclinical studies use rodent-scale dosing in milligrams per kilogram of body weight, and those numbers don't translate cleanly to a human injection protocol the way an FDA-approved drug's label would. Products marketed online as 'TB-500' with specific milligram dosing schedules are following supplier convention, forum consensus, or anecdote, not a peer-reviewed human dosing study. That's a meaningfully different footing than an approved peptide drug you'd find in the Drugs@FDA database ^[21], where dosing comes from actual trial data reviewed by regulators. If you want the practical side of this, including how blends are typically handled once a provider has reviewed a case, our TB-500 storage and shelf life page covers handling questions that come up constantly, and our main TB-500 hub page is the place to start for the evidence landscape overall.

What are the safety concerns with TB-500 vs native thymosin beta-4?

Safety data on TB-500 specifically, in humans, at the doses people are actually using, is thin. Most of what exists is analytical (can we detect it) rather than clinical (what does it do to a person over weeks or months). The 2026 Sports Medicine review on approved versus unapproved peptide therapies is the closest thing to a safety-focused synthesis in the current record, and it explicitly separates approved from unapproved products in its framing ^[11], which is the same separation that should guide a reader's risk tolerance. Because native Tβ4 is an endogenous protein, the theoretical safety profile of the body's own molecule doesn't automatically transfer to a synthetic fragment product manufactured outside pharmaceutical quality control. Purity, dose accuracy, and contamination risk are real variables with unregulated peptide sourcing, separate from whatever the underlying biology might do. For a longer look at adverse effect patterns and who should avoid this compound altogether, see TB-500 long term side effects and TB-500 contraindications. If you're a woman researching this, TB-500 in women covers the sex-specific gaps in the data directly.

Which one should you research further, TB-4 or TB-500?

If you're trying to understand the underlying biology, native thymosin beta-4 is the molecule with the deeper basic-science history: actin binding, cell migration, decades of mechanistic study across wound healing and cardiac research. If you're evaluating a product being sold as an injury-recovery peptide, you're almost certainly looking at TB-500, the synthetic fragment, and you should hold that product to the unapproved-drug standard it actually sits at, not the standard implied by its association with a natural protein. Don't let a seller's use of 'thymosin beta-4' language on a TB-500 listing imply more legitimacy than the product has. They're related. They are not interchangeable, and the regulatory and evidence gaps that apply to TB-500 don't get erased by naming it after its natural cousin.

Frequently asked questions

Is TB-500 a fragment of thymosin beta-4?

TB-500 is marketed as covering the active, actin-binding region of thymosin beta-4, roughly the 17-23 amino acid segment, per a 2012 synthesis and characterization paper that built this exact fragment for doping-detection research ^[1]. It's not the full 43-amino-acid native protein.

Can TB-500 be bought as a standalone product?

Not through a legitimate compounding pharmacy channel. Neither TB-500 nor thymosin beta-4 appears on the FDA's 503A ^[3] or 503B ^[4] bulk drug substance lists. Where it's dispensed with pharmacy oversight, it's part of a combined BPC-157/TB-500 blend, not sold alone.

Is thymosin beta-4 the same drug as TB-500?

No. Thymosin beta-4 is the native, naturally occurring 43-amino-acid protein. TB-500 is a synthetic product sold under that name and studied as a distinct analyte in mass spectrometry work, with its own metabolites tracked separately from native Tβ4 ^[2].

Is TB-500 banned by WADA?

Yes. TB-500 is prohibited in WADA-tested competitive sport, which is part of why the compound has an extensive detection-chemistry literature in equine and human doping-control labs, including dedicated LC-MS methods built specifically to catch it ^[12][13].

Has TB-500 been tested in human clinical trials?

Not in the way an FDA-approved drug would be. The current record is dominated by preclinical, in-vitro, and analytical detection studies. A 2026 Sports Medicine review explicitly separates approved from unapproved peptide products in its safety and efficacy framing, with TB-500 on the unapproved side ^[11].

What's the difference in legal status between TB-4 and TB-500?

Neither is FDA-approved for injury treatment, and neither is on the FDA's bulk drug substance lists for 503A or 503B compounding ^[3][4]. Both sit outside standard pharmaceutical regulation; the practical difference is that TB-500 is the version actively sold and marketed to consumers.

Why is so much TB-500 research about drug testing instead of medicine?

Because doping-control labs, especially in horse racing, needed detection methods before clinical medicine built a trial base. Multiple papers from 2012 to 2017 developed LC-MS, UHPLC, and extraction methods specifically to catch TB-500 in urine and plasma ^{[12][13][14][20]}.

Does TB-500 show up in anti-aging research?

Thymosin-family peptides appear in broader gerontology reviews, including a 2026 Frontiers in Aging paper on therapeutic peptides and healthy aging mechanisms ^[22]. That's a mechanisms review, not clinical proof that TB-500 specifically slows human aging.

Is there a standard dose for TB-500?

No validated human dosing protocol exists in peer-reviewed literature. Preclinical studies use rodent mg/kg dosing that doesn't translate directly to humans. Online dosing schedules come from supplier and forum convention, not trial data.

How is TB-500 detected in drug testing?

Through liquid chromatography-mass spectrometry and related methods. Papers from 2012 through 2016 built assays using LC-MS in equine plasma ^[12], UHPLC-Orbitrap MS/MS in rats ^[2], and solid-phase extraction from human urine ^[20], among other technique papers.

Is BPC-157/TB-500 blend the same as pure TB-500?

No. A BPC-157/TB-500 blend combines two different peptides in one formulation dispensed by a compounding pharmacy after provider review. It is not a standalone TB-500 product, and dosing, sourcing, and oversight differ from unregulated single-peptide vials sold online.

Does native thymosin beta-4 have more research support than TB-500?

Thymosin beta-4 has a longer basic-science history around actin binding and cell migration. TB-500-specific literature leans heavily toward detection chemistry and doping control rather than clinical outcomes, so neither has strong human trial support, but their evidence bases differ in character.

Sources

1. Drug Testing and Analysis, 2012 (PMID 22962027): TB-500 corresponds to the N-terminal acetylated 17-23 fragment of thymosin beta-4, synthesized specifically due to suspected doping potential
2. Journal of Chromatography B, 2024 (PMID 38382158): UHPLC-Q-Exactive Orbitrap MS/MS method quantified TB-500 and its metabolites separately from native protein in in-vitro experiments and rats, screening for wound-healing activity
3. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the substances compounding pharmacies may legally use under section 503A; neither Tβ4 nor TB-500 appears on it
4. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the substances outsourcing facilities may use under section 503B; neither Tβ4 nor TB-500 appears on it
5. Journal of Chromatography A, 2012 (PMID 23084823): LC-MS doping control method developed specifically to detect TB-500 in equine urine and plasma
6. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): LC-MS method for doping control analysis of seven bioactive peptides, including TB-500, in horse plasma
7. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's official page listing and governing bulk substances eligible for 503A compounding
8. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): Current FDA list of nominated bulk substances under review for compounding eligibility
9. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics covering applications, challenges, and future directions
10. American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy
11. Sports Medicine (Auckland), 2026 (PMID 41966639): Review distinguishing safety and efficacy evidence for approved versus unapproved peptide therapies in musculoskeletal injury and athletic performance
12. Analytical Biochemistry, 2017 (PMID 28887173): Studied adsorption effects of doping-relevant peptides including TB-500, insulin lispro, Synacthen, and GHRP-5 on lab plasticware
13. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Reviewed analytical approaches for detecting emerging therapeutics and non-approved drugs including peptides in human doping controls
14. Expert Review of Proteomics, 2014 (PMID 25382550): Reviewed current status and future directions for detecting peptidic drugs, candidates, and analogs in sports doping
15. Journal of Peptide Science, 2015 (PMID 25469748): Described in-vitro models for metabolic studies of small peptide hormones in sport drug testing
16. Journal of Separation Science, 2016 (PMID 26578461): Developed a simplified screening method for peptides under 2kDa via direct urine injection and ion mobility mass spectrometry
17. Journal of Proteomics, 2016 (PMID 27569051): Compared in-vitro metabolism model systems (enzymes, serum, liver/kidney microsomes, S9 fraction) for synthetic doping peptides
18. Drug Testing and Analysis, 2016 (PMID 26472487): Developed solid-phase extraction methods for small bioactive peptides from human urine using cartridges and microelution plates
19. Cornell Law School, 21 U.S.C. § 353a: Statute governing pharmacy compounding conditions under section 503A
20. Frontiers in Aging, 2026 (PMID 42021992): Reviewed mechanisms and applications of therapeutic peptides, including thymosin-family peptides, in gerontology and healthy aging
21. Drugs@FDA, FDA-approved drug products database: Official database showing which drug products, with their trial-based dosing, carry FDA approval, unlike TB-500 or thymosin beta-4